INDGN578.00

Indegene Ltd.

· Pharma & Health
₹ CrorePeersSYNGENELTTSGRANULESJUBLPHARMAKIMSERISEMCUREONESOURCEMcap ₹13,901 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
INDGN
FY26
SYNGENE
FY26
LTTS
FY26
GRANULES
FY26
Peer
Median
Valuation — at last close
P/E34.57×48.79×27.92×36.64×36.64× -6%
P/B4.43×3.20×5.50×4.37×4.37× +1%
EV/EBITDA20.19×16.11×16.87×19.13×16.87× +20%
Market Cap₹13,901 Cr₹15,471 Cr₹35,723 Cr₹22,215 Cr₹22,215 Cr -37%
Growth
Revenue CAGR 3Y5.40%11.12%5.95%5.95%
Revenue CAGR 5Y11.35%15.07%10.63%11.35%
Net Income CAGR 3Y-11.98%2.95%4.82%2.95%
Revenue YoY (latest Q)39.73%-15.84%2.59%22.04%2.59% +1434%
Net Income YoY (latest Q)-0.17%-110.38%12.97%59.77%12.97% -101%
Profitability
EBITDA Margin17.63%24.57%17.60%22.09%22.09% -20%
Net Income Margin11.43%8.47%11.65%11.09%11.09% +3%
Return on Common Equity12.78%6.54%19.70%11.70%11.70% +9%
Return on Capital Employed13.94%8.46%20.08%15.80%15.80% -12%
Return on Assets8.68%4.49%12.21%7.71%7.71% +13%
Credit & Quality
Total Debt/Equity0.00×0.00×0.00×0.26×0.00×
Interest Coverage25.52×9.54×24.80×7.77×9.54× +168%
Scale — latest FY
Revenue / Total Income₹3,511 Cr₹3,739 Cr₹10,996 Cr₹5,366 Cr₹5,366 Cr -35%
Net Income₹401 Cr₹317 Cr₹1,281 Cr₹595 Cr₹595 Cr -33%
Total Assets₹4,620 Cr₹7,055 Cr₹10,489 Cr₹7,720 Cr₹7,720 Cr -40%
EPS₹16.72₹7.87₹120.71₹24.47₹24.47 -32%
Book Value per Share₹130.51₹120.11₹612.47₹205.21₹205.21 -36%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.